Immunological testing for malaria and blood donor deferral: The experience of the Ca' Granda Polyclinic Hospital in Milan

Romualdo Grande, Gianna Petrini, Iris Silvani, Barbara Simoneschi, Maurizio Marconi, Erminio Torresani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background. Current European regulations require a deferral period of 6 months or 3 years, depending on the risk of exposure, for prospective blood donors at risk of malaria. This period may be reduced to 4 months if an immunological or molecular genomic test is negative at each donation, but Italian regulations have not adopted this provision. As cases of transfusion-transmitted malaria have been recorded in medical literature in blood donors deferred for 3 years and not tested, the Immunohaematology and Transfusion Centre of the Ca' Grande Polyclinic Hospital in Milan decided to introduce immunological testing for all donors at risk of malaria. Materials and methods. Four hundred and twelve blood donors at risk of malaria, who had lived in a malarial area during the first 5 years of life or for more than 6 consecutive months, were tested for malarial antibodies using an enzyme immunoassay kit. The kit (Malaria EIA, Newmarket, UK) uses four recombinant antigens specific for P. falciparum and P. vivax and with cross-reactivity for P. ovale and P. malariae. The kit detects total immunoglobulin antibodies against P. falciparum and P. vivax and shows 80% cross-reactivity with P. ovale and 67% with P. malariae. Antibody-positive samples were further checked by an immunochromatographic test for P. falciparum, P. vivax, P. ovale and P. malariae antigens and by haemoscopy (thin film and thick smear). Results. Italian citizens accounted for 16.8% (69/412) of the whole group of donors examined. We found that 8.7% of the donors who were classified as being at risk of malaria were positive for total immunoglobulin antibodies. Only one Italian citizen resulted positive for the test. The positive candidates were deferred from blood donation. None of the antibody-positive donors was confirmed positive by the immunochromatographic test and by haemoscopy. Conclusion. The introduction of a malarial screening test in the assessment of blood donor eligibility may increase the safety of blood donations, but could further reduce blood availability. If immunological testing were to be accepted nationally as a valid method of assessing the risk of malaria, more than 90% of the donors who are currently deferred for 3 years could be accepted 4 months after their last visit to an endemic area, thus increasing the availability of blood.

Original languageEnglish
Pages (from-to)162-166
Number of pages5
JournalBlood Transfusion
Volume9
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Blood Donors
Malaria
Tissue Donors
Antibodies
Immunoglobulins
Antigens
Immunoenzyme Techniques
Safety

Keywords

  • Donor's risk
  • Enzyme immunoassay
  • Transfusion-transmitted malaria

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

Immunological testing for malaria and blood donor deferral : The experience of the Ca' Granda Polyclinic Hospital in Milan. / Grande, Romualdo; Petrini, Gianna; Silvani, Iris; Simoneschi, Barbara; Marconi, Maurizio; Torresani, Erminio.

In: Blood Transfusion, Vol. 9, No. 2, 2011, p. 162-166.

Research output: Contribution to journalArticle

Grande, R, Petrini, G, Silvani, I, Simoneschi, B, Marconi, M & Torresani, E 2011, 'Immunological testing for malaria and blood donor deferral: The experience of the Ca' Granda Polyclinic Hospital in Milan', Blood Transfusion, vol. 9, no. 2, pp. 162-166. https://doi.org/10.2450/2011.0158-09
Grande, Romualdo ; Petrini, Gianna ; Silvani, Iris ; Simoneschi, Barbara ; Marconi, Maurizio ; Torresani, Erminio. / Immunological testing for malaria and blood donor deferral : The experience of the Ca' Granda Polyclinic Hospital in Milan. In: Blood Transfusion. 2011 ; Vol. 9, No. 2. pp. 162-166.
@article{1b892a2d21e74a9c8ee8111b94a2433d,
title = "Immunological testing for malaria and blood donor deferral: The experience of the Ca' Granda Polyclinic Hospital in Milan",
abstract = "Background. Current European regulations require a deferral period of 6 months or 3 years, depending on the risk of exposure, for prospective blood donors at risk of malaria. This period may be reduced to 4 months if an immunological or molecular genomic test is negative at each donation, but Italian regulations have not adopted this provision. As cases of transfusion-transmitted malaria have been recorded in medical literature in blood donors deferred for 3 years and not tested, the Immunohaematology and Transfusion Centre of the Ca' Grande Polyclinic Hospital in Milan decided to introduce immunological testing for all donors at risk of malaria. Materials and methods. Four hundred and twelve blood donors at risk of malaria, who had lived in a malarial area during the first 5 years of life or for more than 6 consecutive months, were tested for malarial antibodies using an enzyme immunoassay kit. The kit (Malaria EIA, Newmarket, UK) uses four recombinant antigens specific for P. falciparum and P. vivax and with cross-reactivity for P. ovale and P. malariae. The kit detects total immunoglobulin antibodies against P. falciparum and P. vivax and shows 80{\%} cross-reactivity with P. ovale and 67{\%} with P. malariae. Antibody-positive samples were further checked by an immunochromatographic test for P. falciparum, P. vivax, P. ovale and P. malariae antigens and by haemoscopy (thin film and thick smear). Results. Italian citizens accounted for 16.8{\%} (69/412) of the whole group of donors examined. We found that 8.7{\%} of the donors who were classified as being at risk of malaria were positive for total immunoglobulin antibodies. Only one Italian citizen resulted positive for the test. The positive candidates were deferred from blood donation. None of the antibody-positive donors was confirmed positive by the immunochromatographic test and by haemoscopy. Conclusion. The introduction of a malarial screening test in the assessment of blood donor eligibility may increase the safety of blood donations, but could further reduce blood availability. If immunological testing were to be accepted nationally as a valid method of assessing the risk of malaria, more than 90{\%} of the donors who are currently deferred for 3 years could be accepted 4 months after their last visit to an endemic area, thus increasing the availability of blood.",
keywords = "Donor's risk, Enzyme immunoassay, Transfusion-transmitted malaria",
author = "Romualdo Grande and Gianna Petrini and Iris Silvani and Barbara Simoneschi and Maurizio Marconi and Erminio Torresani",
year = "2011",
doi = "10.2450/2011.0158-09",
language = "English",
volume = "9",
pages = "162--166",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "2",

}

TY - JOUR

T1 - Immunological testing for malaria and blood donor deferral

T2 - The experience of the Ca' Granda Polyclinic Hospital in Milan

AU - Grande, Romualdo

AU - Petrini, Gianna

AU - Silvani, Iris

AU - Simoneschi, Barbara

AU - Marconi, Maurizio

AU - Torresani, Erminio

PY - 2011

Y1 - 2011

N2 - Background. Current European regulations require a deferral period of 6 months or 3 years, depending on the risk of exposure, for prospective blood donors at risk of malaria. This period may be reduced to 4 months if an immunological or molecular genomic test is negative at each donation, but Italian regulations have not adopted this provision. As cases of transfusion-transmitted malaria have been recorded in medical literature in blood donors deferred for 3 years and not tested, the Immunohaematology and Transfusion Centre of the Ca' Grande Polyclinic Hospital in Milan decided to introduce immunological testing for all donors at risk of malaria. Materials and methods. Four hundred and twelve blood donors at risk of malaria, who had lived in a malarial area during the first 5 years of life or for more than 6 consecutive months, were tested for malarial antibodies using an enzyme immunoassay kit. The kit (Malaria EIA, Newmarket, UK) uses four recombinant antigens specific for P. falciparum and P. vivax and with cross-reactivity for P. ovale and P. malariae. The kit detects total immunoglobulin antibodies against P. falciparum and P. vivax and shows 80% cross-reactivity with P. ovale and 67% with P. malariae. Antibody-positive samples were further checked by an immunochromatographic test for P. falciparum, P. vivax, P. ovale and P. malariae antigens and by haemoscopy (thin film and thick smear). Results. Italian citizens accounted for 16.8% (69/412) of the whole group of donors examined. We found that 8.7% of the donors who were classified as being at risk of malaria were positive for total immunoglobulin antibodies. Only one Italian citizen resulted positive for the test. The positive candidates were deferred from blood donation. None of the antibody-positive donors was confirmed positive by the immunochromatographic test and by haemoscopy. Conclusion. The introduction of a malarial screening test in the assessment of blood donor eligibility may increase the safety of blood donations, but could further reduce blood availability. If immunological testing were to be accepted nationally as a valid method of assessing the risk of malaria, more than 90% of the donors who are currently deferred for 3 years could be accepted 4 months after their last visit to an endemic area, thus increasing the availability of blood.

AB - Background. Current European regulations require a deferral period of 6 months or 3 years, depending on the risk of exposure, for prospective blood donors at risk of malaria. This period may be reduced to 4 months if an immunological or molecular genomic test is negative at each donation, but Italian regulations have not adopted this provision. As cases of transfusion-transmitted malaria have been recorded in medical literature in blood donors deferred for 3 years and not tested, the Immunohaematology and Transfusion Centre of the Ca' Grande Polyclinic Hospital in Milan decided to introduce immunological testing for all donors at risk of malaria. Materials and methods. Four hundred and twelve blood donors at risk of malaria, who had lived in a malarial area during the first 5 years of life or for more than 6 consecutive months, were tested for malarial antibodies using an enzyme immunoassay kit. The kit (Malaria EIA, Newmarket, UK) uses four recombinant antigens specific for P. falciparum and P. vivax and with cross-reactivity for P. ovale and P. malariae. The kit detects total immunoglobulin antibodies against P. falciparum and P. vivax and shows 80% cross-reactivity with P. ovale and 67% with P. malariae. Antibody-positive samples were further checked by an immunochromatographic test for P. falciparum, P. vivax, P. ovale and P. malariae antigens and by haemoscopy (thin film and thick smear). Results. Italian citizens accounted for 16.8% (69/412) of the whole group of donors examined. We found that 8.7% of the donors who were classified as being at risk of malaria were positive for total immunoglobulin antibodies. Only one Italian citizen resulted positive for the test. The positive candidates were deferred from blood donation. None of the antibody-positive donors was confirmed positive by the immunochromatographic test and by haemoscopy. Conclusion. The introduction of a malarial screening test in the assessment of blood donor eligibility may increase the safety of blood donations, but could further reduce blood availability. If immunological testing were to be accepted nationally as a valid method of assessing the risk of malaria, more than 90% of the donors who are currently deferred for 3 years could be accepted 4 months after their last visit to an endemic area, thus increasing the availability of blood.

KW - Donor's risk

KW - Enzyme immunoassay

KW - Transfusion-transmitted malaria

UR - http://www.scopus.com/inward/record.url?scp=79953690252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953690252&partnerID=8YFLogxK

U2 - 10.2450/2011.0158-09

DO - 10.2450/2011.0158-09

M3 - Article

C2 - 21251462

AN - SCOPUS:79953690252

VL - 9

SP - 162

EP - 166

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 2

ER -